Development and validation of a high-confidence diagnostic model integrating ctDNA methylation and serum biomarkers for early-stage hepatocellular carcinoma detection - PubMed
a day ago
- #ctDNA methylation
- #Early detection
- #Hepatocellular carcinoma
- Development of GAMAD, a diagnostic model integrating ctDNA methylation and serum biomarkers for early-stage hepatocellular carcinoma (HCC) detection.
- GAMAD demonstrated superior performance with 74.6% sensitivity, 88.1% specificity, and AUC of 0.862 compared to existing biomarkers.
- Optimized for early-stage HCC, GAMAD achieved 80.5% sensitivity, 90.4% specificity, and AUC of 0.934 in the validation cohort.
- In independent testing, GAMAD showed 86.5% sensitivity for stage 0/A and 91.7% for stage B-C HCC (AUC 0.952).
- Intended as an adjunct to standard imaging for high-risk populations to improve early diagnosis rates.
- Multicenter prospective trial involved 1,692 patients (476 HCC, 645 hepatitis, 443 cirrhosis, 128 healthy).
- Ethical approval obtained from multiple hospitals, with informed consent from all participants.